Table 4.
Estimating the association between baseline serum alkaline phosphatase (ALP) and new-onset diabetes evaluated with risk ratio (RR)
| ALP, IU/L | N | No. of events (%) | Crude model | Adjusted model* | ||
|---|---|---|---|---|---|---|
| RR (95% CI) | P value† | RR (95% CI) | P value† | |||
| New-onset diabetes | ||||||
| Continuous, per SD (30.5 IU/L) increment | 14,393 | 1549 (10.8) | 1.06 (1.01,1.12) | 0.011 | 1.06 (1.00,1.12) | 0.034 |
| Quartiles | ||||||
| Q1 (< 79) | 3486 | 343 (9.8) | 1.00 (ref.) | 1.00 (ref.) | ||
| Q2 (79- < 96) | 3623 | 381 (10.5) | 1.07 (0.93,1.24) | 0.372 | 1.09 (0.94,1.26) | 0.274 |
| Q3 (96- < 116) | 3577 | 390 (10.9) | 1.12 (0.97,1.29) | 0.166 | 1.12 (0.96,1.30) | 0.143 |
| Q4 (≥ 116) | 3707 | 435 (11.7) | 1.19 (1.04,1.38) | 0.015 | 1.21 (1.03,1.41) | 0.018 |
| P for trend | 0.013 | 0.019 | ||||
ALP serum alkaline phosphatase, CI confidence interval, eGFR estimated glomerular filtration rate, RR risk ratio, SD standard deviations, SBP systolic blood pressure
*Adjusted for age, sex, study center, treatment group, body mass index (BMI), smoking, alcohol drinking, family history of diabetes, SBP, fasting glucose (FG), total cholesterol (TC), triglycerides (TG), eGFR, folate, total homocysteine and the use of antihypertensive drugs at baseline, as well as time-averaged SBP during the treatment period
†In comparison with the first quartile